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Using the Amplatzer Septal OccluderSergio Bartakian, MD, Howaida G. El-Said, MD, PHD, Beth Printz, MD, PHD,
John W. Moore, MD, MPH
San Diego, CaliforniaObjectives This study sought to determine whether transthoracic echocardiography (TTE) can provide
safety and efﬁcacy equivalent to transesophageal echocardiography (TEE) for assessment and
guidance of transcatheter atrial septal defect (ASD) closure in pediatric patients.
Methods We performed a prospective randomized trial of ASD closure using the Amplatzer septal
occluder (ASO) from March 2008 to April 2012. Inclusion criteria were isolated secundum ASD, age 2 to
18 years, and adequate TTE windows. Forty patients were enrolled and randomized to either TEE or
TTE. In the TEE group, we used “stop ﬂow” balloon sizing to determine device size. In the TTE group, we
used the average ASD diameter times 1.2 (scaled). Patients were followed up to 1 year.
Results Patient general and hemodynamic characteristics were similar in both groups. Procedural
success was 100% in both groups. The average TEE stop ﬂow diameter was similar to the scaled TTE
diameter (15.35  4.62 mm vs. 16.57  5.47 mm; p ¼ 0.46). Device size (16.0  4.94 mm vs.
16.37  5.05 mm, p ¼ 0.82) and ratio of device to defect size (1.0  0.06 vs. 0.99  0.03, p ¼ 0.52) were
also similar. Total procedure (70.6  22.98 min vs. 51.1  17.61 min, p ¼ 0.005), room (126.8  28.41
min vs. 95.7  20.53 min, p ¼ 0.0004), and ﬂuoroscopy (13.6  6.17 min vs. 8.9  8.45 min, p ¼ 0.007)
times were all signiﬁcantly shorter in the TTE group. Neither group had signiﬁcant complications
during the procedure nor in follow-up. Rates of shunt resolution were similar between groups.
Conclusions This study suggests that in selected pediatric patients, use of TTE is as efﬁcacious and
safe as TEE for assessment and guidance of ASD occlusion using the ASO. TTE also may offer the
additional safety beneﬁt of reduced ﬂuoroscopy exposure. (J Am Coll Cardiol Intv 2013;6:974–80)
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Abbreviations
and Acronyms
ASD = atrial septal defect
ASO = Amplatzer septal
occluder
ECG = electrocardiogram
ICE = intracardiac
echocardiography
TEE = transesophageal
echocardiography
TTE = transthoracic
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975Successful nonsurgical closure of atrial septal defect (ASD)
was ﬁrst reported in 1974 by King and Mills (1). Recent
studies have demonstrated the safety and efﬁcacy of percu-
taneous ASD occlusion, making it the preferred method of
treatment at most centers (2–4).
Soon after it received U.S. Food and Drug Administra-
tion approval in 2001, the Amplatzer septal occluder (ASO)
became the most widely used device for percutaneous ASD
closure. Transesophageal echocardiography (TEE) was
required in the pivotal trial of the ASO, and continues to be
the most common ultrasound technology used for deﬁnitive
ASD assessment, device selection, and device guidance
during implantation (2,5).
We have previously reported experience implanting the
ASO using transthoracic echocardiography (TTE) (6).
Because there have been no studies directly comparing TEE
with TTE, we undertook this study to determine whether
TTE can provide safety and efﬁcacy equivalent to TEE for
assessment, device selection, and guidance of transcatheter
ASD occlusion, using the ASO in children.
Methods
Study design. This study was approved by the Rady Chil-
dren’s Hospital/University of California–San Diego insti-
tutional review board. All patients between 2 and 18 years of
age, discovered to have an isolated secundum ASD
amenable to device closure, were considered eligible. All
patients were initially evaluated using TTE at the time of
diagnosis. We excluded patients not meeting age criteria as
well as those who had multiple ASDs, or had other hemo-
dynamically signiﬁcant cardiac lesions. This was simply to
ensure uniformity between groups and to exclude any
potential confounders. We excluded any patient with previ-
ously diagnosed coagulation defects and those with any
history of esophageal varices, esophageal obstruction, or past
radiation therapy to the area. We also excluded any patient
who was deemed not to have adequate TTE windows on
initial screening exam, deﬁned as the ability to see the defect
well from 3 perpendicular planes of imaging. BetweenMarch
2008 and April 2012, 40 patients met the criteria, were
enrolled, and were then randomized to 1 of 2 groups: TEE
versus TTE.
Study outcomes and deﬁnitions. The primary outcome was
procedural success, deﬁned as successful implantation of the
device without embolization or malposition. The study
tested the hypothesis that TTE was noninferior to TEE for
device selection, guidance, and assessment in select patients
with isolated secundum ASD. Sample size estimates were
based on published statistics formulae (7), and we deter-
mined that 20 patients per study arm would result in the
needed power of 0.80 at an alpha of 0.05.
Secondary outcomes included procedure time, ﬂuoroscopy
time, complications, and correlation of device size to “scaled”TTE ASD diameter. The procedure time was deﬁned as the
time from initial skin puncture to hemostasis being achieved
at case end. The room time was deﬁned as the time from
patient entry into and exit from the catheterization lab.
Informed consent was obtained for all patients. Patients in
both study groups underwent our routine catheterization
protocol for ASD occlusion. This included use of general
anesthesia, administration of heparin and monitoring of
activated coagulation time, femoral venous access, right
and left heart catheterization, and measurement of intra-
cardiac pressures and saturations. All patients had an ASO
implanted using standard catheterization techniques by 1 of
2 senior interventional cardiologists (J.W.M. andH.E.S.). All
patients received intravenous antibiotics during the procedure.
Procedure. TTE GROUP. While the patient was being
prepared in the catheterization laboratory, the TTE previ-
ously performed in clinic was reviewed, and measurements
of the ASD were obtained from 3 standard views: para-
sternal short axis, apical 4 chamber, and subcostal sagittal (6)
(Fig. 1).
These 3 measurements were
averaged, and this average
diameter was then multiplied by
a factor of 1.2 to derive a “scaled”
ASD diameter. A device equal to
(or just larger in the case of a
half size or odd number) to the
scaled diameter was selected for
implantation. If the images from
the initial diagnostic TTE were
not considered to be adequate,
additional TTE imaging was
performed as needed in the
catheterization laboratory. This was carried out following
induction with general anesthesia and before the patient was
prepped. The implant procedure was guided using ﬂuoros-
copy. Once the device was in place and felt to be in good
position, the drape was pulled back, allowing the echocar-
diographers access to the chest to perform a brief assessment
of the device. If TTE imaging was reassuring and conﬁr-
matory of adequate positioning, the patient was re-draped,
and the device released under ﬂuoroscopic observation.
For device assessment, before release, the 3 views
described in the previous text were used to ensure the
septum was captured between the left and right atrial discs
(Fig. 2). In the parasternal short-axis view, the retroaortic
rim was evaluated. If this rim was deﬁcient, splaying around
the aorta was considered to conﬁrm adequate device posi-
tion. In the 4-chamber view, capture of the mitral (anterior-
inferior) rim was evaluated, as was the pulmonary venous
(posterior-superior) rim. Finally, in the subcostal sagittal
(bicaval) view, capture of the superior vena cava (superior)
rim was evaluated, as was the appropriate inferior device rim
capture or device alignment (suggesting capture) of the
echocardiography
Figure 1. Pre-Procedure ASD Assessment
(A) The parasternal short-axis view, (B) apical 4-chamber view, and (C) subcostal sagittal view. Scaled formula: ([1.4 þ 1.16 þ 1.0]/3)  1.2 ¼ 1.42 cm; therefore,
a size 14 device. Ao ¼ cross section of the aortic valve; ASD ¼ atrial septal defect; LA ¼ left atrium; LV ¼ left ventricle; RA ¼ right atrium; RV ¼ right ventricle.
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976inferior vena cava (posterior-inferior) rim. The sagittal view
is the most complicated because the device does not acquire
its ﬁnal conﬁguration until release of the delivery cable, as
seen in Figures 2C and 2D. The operator may pull on the
device cable gently to separate the right and left discs,
facilitating visualization of rim capture in all views.
TEE GROUP. TEE was performed in the catheterization
laboratory after general anesthesia was initiated. ASDFigure 2. Device Guidance
Parasternal short-axis (A), apical 4-chamber (B), and subcostal sagittal (C) transthora
Comparison of panels C and D shows the drastic change in conformation of the de
DC ¼ delivery cable; IVC ¼ inferior vena cava; MV ¼ mitral valve; SVC ¼ superior vedimensions were obtained from the bicaval, aortic short-axis,
and modiﬁed 4-chamber views. During the diagnostic
portion of the catheterization, “stop ﬂow” balloon sizing of
the ASD was performed using TEE (8,9) (Fig. 3). A device
equal to (or just larger in the case of a fraction or odd number)
the stop ﬂow diameter was selected for implantation. The
implant procedure was guided using TEE and ﬂuoroscopy.
After catheterization, all patients were treated with low-
dose aspirin therapy and remained in the hospital overnightcic echocardiogram views during device positioning with cable attached.
vice after release in the subcostal sagittal view. AO ¼ aorta; AS ¼ atrial septum;
na cava; TV ¼ tricuspid valve; other abbreviations as in Figure 1.
Figure 3. Balloon Stop Flow Measurement
Atrial septal defect during transesophageal echocardiography.
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977for recovery and observation. Patients received a chest x-ray,
electrocardiogram (ECG), and TTE before hospital
discharge. All patients had a 1-month as well as a 6- to 12-
month outpatient follow-up evaluation. At these evaluations,
each patient received a chest x-ray, ECG, and TTE.
Additional studies and follow-up evaluations were per-
formed as deemed clinically appropriate.
Data collection. Demographic information was collected
including age, sex, height, and weight at the time of the
procedure. Experienced echocardiographers interpreted all
echocardiograms (procedural and follow-up points). Reports
and images of TTEs and TEEs were reviewed to collect data
pertaining to the defect diameters, stop ﬂow balloon diam-
eters, residual ASD shunting, as well as information
regarding potential negative effects of device placement
(pericardial effusion, new or changes in valvar insufﬁciency,
and so on). Catheterization reports were used to collect
hemodynamic data (total pulmonary to systemic output ratio
[Q p/Qs ratio] and pulmonary vascular resistance), times
(room, procedural, ﬂuoroscopy), scaled diameters, device
sizes, stop ﬂow measurements, as well as information
regarding complications. Follow-up ECGs, Holter reports,
and clinic notes were reviewed.
Statistical analysis. For all patient and procedural data,
continuous variables are presented as mean  SD or median
(range), depending on whether or not they were normally
distributed. For all variables, a Grubb’s test was performed to
detect the presence of any outliers. Where there was missing
data, the number of nonmissing values is reported for that
variable. Percentages are provided for categorical variables.
For comparisons of continuous variables (e.g., procedure
time) between 2 groups, an unpaired Student t test or
Wilcoxon rank sum test for related samples was used for
normally distributed or skewed data, respectively. For
comparison of categorical variables (presence of residual) at
different time points, a Fisher exact test was used with
2-tailed p values. A 2-tailed p value <0.05 was consideredstatistically signiﬁcant. Pearson’s correlation was performed
as a measure of assessing the relationships between
measurements and device size. All statistical analyses were
performed using GraphPad Software (GraphPad Software,
La Jolla, California).
Results
During the study period, there were a total of 84 ASD
device closures using the ASO. Forty patients met study
criteria and were initially enrolled. Of the 44 not enrolled,
14 refused consent and 18 met exclusion criteria. Of these
18, 5 patients required multiple devices, 5 had signiﬁcant
coexisting cardiac diagnoses, 5 failed to meet age criteria,
and 3 had procedures performed by a private cardiologist not
taking part in the study. The remaining 12 patients were not
enrolled due to poor TTE imaging windows. The ages for
these 12 patients ranged from 3 to 18 years, with a median
of 10 years. We later excluded 2 additional patients, leaving
a ﬁnal population of 38 patients (19 in each group). The 2
patients were excluded due to the discovery of additional or
disqualifying cardiac defects during their procedural echo-
cardiograms. In the TEE group, 1 patient was found to have
a sinus venosus ASD (deﬁcient superior vena cava rim), and
in the TTE group, 1 patient was discovered to have mo-
derate right pulmonary vein stenosis in addition to an ASD;
both patients were referred for surgery.
General patient characteristics showed no differences
between the 2 groups (Table 1). Hemodynamic and echo-
cardiographic data are depicted in Table 2. Hemodynamic
variables, including Q p/Qs and pulmonary vascular resis-
tance were similar between groups.
The device sizes used were similar in both groups as was
the average defect size as measured by TEE or TTE. There
was no difference when we compared the stop ﬂow diameter
in the TEE group with the scaled diameter in the TTE
group. The ratio of device size to the scaled diameter in the
Figure 4. Pearson’s Correlation
Correlation of transthoracic echocardiography (TTE) (upper panel) and
transesophageal echocardiography (lower panel) device-to-defect ratio.
Table 1. General Patient Characteristics
TEE
(n ¼ 19)
TTE
(n ¼ 19) p Value
Age, yrs 6.5  4.8 5.5  3.4 0.47
Weight, kg 25  17.4 20.8  12.2 0.4
Height, cm 112.8  28.53 109.8  23.34 0.72
Male 9 (47) 12 (63)
Values are mean  SD or n (%).
TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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978TTE group (0.99  0.03) was also not different from the
ratio of device size to stop ﬂow diameter in the TEE group
(1.0  0.06; p ¼ 0.52), further suggesting the 2 methods are
equally efﬁcacious in determining the device size needed for
closure. The Pearson correlation for the scaled diameter to
the ﬁnal deployed device size in the TTE group was slightly
better than the correlation of stop ﬂow balloon diameter to
the ﬁnal deployed device size in the TEE group (Fig. 4). To
test our scaled formula further, we retrospectively evaluated
the initial screening TTE of a subset of 13 patients in the
TEE group who had adequate imaging windows to make
our required measurements. When we applied our scaled
formula to this subset and compared it with either the TTE
group’s mean scaled diameter (Table 2), or the balloon stop
ﬂow measurement we had used in the procedure, there was
no signiﬁcant difference (scaled TTE in TEE group, 14.82
 4.59 mm vs. stop ﬂow 15.35  4.62 mm; p ¼ 0.72),
implying no beneﬁt to having used TEE in these patients.
We also compared the individual scaled diameters of this
subset of patients against their balloon stop ﬂow diameters
and again found a strong correlation (Fig. 5).
Procedural success was 100% (19 of 19) in both study
groups. There were no major complications in either group.
There were a total of 5 minor complications, 1 in the TTE
group (5%) and 4 in the TEE group (21%; p ¼ 0.35), as
described in Table 3.
In the TTE group, 1 patient experienced a brief episode
of accelerated junctional rhythm while in recovery. HeTable 2. Hemodynamic and Echocardiographic Data
TEE Group TTE Group p Value
Qp/Qs 1.79  0.59 1.87  0.49 0.65
PVR, Wood units  m2 1.03  0.43 0.95  0.47 0.57
Device size, mm 16.0  4.94 16.37  5.05 0.82
Mean defect size
(2D imaging), mm
14.11  5.07 13.81  4.56 0.85
TEE stop ﬂow vs.
TTE scaled, mm
15.35  4.62 16.57  5.47 0.46
Scaled TTE diameter, mm 14.82  4.6 (n ¼ 13) 16.57  5.47 0.35
Values are mean  SD.
2D ¼ 2-dimensional; PVR ¼ pulmonary vascular resistance; Qp/Qs ¼ total pulmonary to
systemic output ratio; other abbreviations as in Table 1.received a single dose of propranolol, which terminated the
tachycardia without recurrence. The 3 measurements ob-
tained of his defect were 15, 16, and 17.5 mm (average
16.17  1.2 ¼ 19.4 mm), as described in the Methods
section. Based on these measurements, a 19-mm ASO was
successfully deployed. All follow-up ECGs, as well as
a Holter study, were normal at 9 months of follow-up.Figure 5. Scatter Plot of TEE Group Patients Scaled Diameter
Scatter plot showing relationship of individual TEE balloon sizing diameters to
same patient’s scaled diameter by TTE, for subset of 13 patients in TEE group.
Table 3. Complications
Patient# Modality
Age
(Years)
Weight
(kg) Complication
Device Size
(mm) ASD Average
ASD Fluoro Size
(mm) Follow-Up
1 TTE 2.5 14.2 Tachycardia in recovery 19 16.17 n/a 9 months
2 TEE 2 10 Hypotension 12 n/a 12.1 4 yrs
3 TEE 12.1 56.5 Brief atrial ﬂutter 18 n/a 18 2 yrs 5 months
4 TEE 3.9 14.3 SVT/1 heart block 22 n/a 21 1 yr 7 months
5 TEE 3.75 15.4 Pericardial effusion 24 n/a 22 4 months
ASD ¼ atrial septal defect; SVT ¼ supraventricular tachycardia; other abbreviations as in Table 1.
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979In the TEE group, Patient #2 experienced a period of
hypotension during the procedure and was started on
a dopamine infusion by the anesthesiologist. He recovered
with no further sequelae. Patient #3 had a brief episode of
hemodynamically insigniﬁcant atrial ﬂutter while establish-
ing wire position. He was electrically cardioverted without
further incident. Patient #4 had a very brief episode of
supraventricular tachycardia during the case, which self-
resolved. While the patient was in recovery, an ECG was
performed that showed ﬁrst-degree heart block. This was
resolved by the next morning’s repeat ECG. The patient was
discharged and has not had a recurrence of the supraven-
tricular tachycardia or ﬁrst-degree heart block in 19 months
of follow-up. Finally, Patient #5 exhibited a new, although
trivial, pericardial effusion on his 1-month follow-up TTE.
This was resolved, without treatment, on a repeat TTE at
2 months post-procedure.
There were statistically signiﬁcant reductions in procedure
time, room time, and ﬂuoroscopy time in the TTE group
(Table 4). The rates of shunt resolution were also similar in
both groups at 1 day, 1 month, and long-term follow-up
between 6 and 12 months (Table 5).
Discussion
As early as 1990, the use of TEE for transcatheter guidance
of ASD closure has been described and shown to be feasible
(10). The fact that TEE quickly became the preferred
modality employed is in large part due to the momentum
garnered by its required use in the pivotal studies (2–5). As
well, some believe that invasive imaging is simply better for
evaluating an ASD because it may allow for improved visu-
alization of thin membranes or other subtle structures (11).Table 4. Modality Characteristics
TEE Group TTE Group p Value
Procedure time, min 70.63  22.98 51.05  17.61 0.0056
Room time, min 126.84  28.41 95.74  20.53 0.0004
Fluoroscopy time, min 13.57  6.17 8.99  8.45 0.007
Contrast, ml 2.41  4.00 0.89  1.45 0.12
Values are mean  SD
Abbreviations as in Table 1.Recently, echocardiography studies have reported on the use
of intracardiac echocardiography (ICE) for procedural guidance
of percutaneous ASD closure, and the use of ICE has
been recommended (12–14).Althoughwe agreeTEEand ICE
may provide better resolution in evaluation of cardiac structures,
we have found that TTE alone is sufﬁcient for evaluation of
isolated secundum ASD and guidance of device selection
and implantation in most patients with adequate windows.
Although relatively safe, TEE is a source of some addi-
tional patient risk and requires general anesthesia when used
in children (15–18). ICE offers an alternative that does not
require general anesthesia; however, it requires a second
large venous access, which may not be possible in smaller
patients, and also adds some additional risk.
Previously, we described the use of TTE for guidance of
transcatheter ASD closure (6). Since that time, there have
been only a few publications reporting the usefulness of
TTE for this purpose (19,20). Zanjani et al. (20) recently
published their experience, describing the usefulness of
TTE, particularly in areas where TEE or ICE are not
available. TTE is more widely available everywhere children
are evaluated for ASD closure. Further, we believe that TTE
use remains limited partly because of the dearth of studies
demonstrating the safety and the efﬁcacy of using it.
To date, there are no controlled, prospective, randomized
studies related to the use of echocardiography in percuta-
neous ASD closure.
In our study, we demonstrated that using TTE images to
calculate a “scaled” defect size and then using it to predict
the device size needed gives similar results to use of the stop
ﬂow diameter by TEE. The 3 perpendicular imaging planes
we used for making our measurements, we feel, represent an
accurate circumferential diameter of the defect, similar to
balloon sizing. We derived our scaled formula after review ofTable 5. Shunt Resolution
TEE TTE p Value
1 day 12/19 11/19 1.0
1 month 12/18 12/18 1.0
6–9 months 15/15 16/17 1.0
Values are n/total n.
Abbreviations as in Table 1.
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980previous large studies that reported device-to-defect ratios
ranging from 1 to 1.4 (2,4,9) and from the long-time
personal observations of the senior author.
Our study suggests that TTEmay be as safe and effective as
TEE in the assessment and guidance of ASO delivery for
ASD device closure, in a select group of patients. TTE may
also offer the added beneﬁt of signiﬁcantly reduced exposure
to ﬂuoroscopic radiation and obviates the need for an addi-
tional cardiologist in the catheterization laboratory to perform
the procedure. There is also the possible beneﬁt of eliminating
the requirement for general anesthesia. This, combined with
the signiﬁcantly shorter room and procedure times and
reduced personnel and equipment requirements, may provide
signiﬁcant cost reductions, which merit further study.
Study limitations. Patient selection for adequate TTE
windows is subjective and may vary between operators. The
small sample size of our study is also a limitation, and more
research is needed to conﬁrm these results and validate the
scaled diameter. Method is limited to only isolated secun-
dum defects and not for multiple ASDs.
Conclusions
The results of this study suggest that TTE may be as efﬁ-
cacious and safe as TEE for assessment and guidance of
transcatheter ASD closure with the ASO in children with
adequate TTE windows. In addition, use of TTE appears to
have cost and safety advantages because of shorter room,
procedure, and ﬂuoroscopy times. The study results support
use of less invasive, less costly TTE in selected patients
undergoing ASD closure with the ASO.
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